Shen Fei, Liu Maojing, Pei Fei, Yu Li, Yang Xiangdong
Department of Nephrology, Qi Lu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
Department of Cardiovascular Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250012, P.R. China.
Oncol Lett. 2021 Dec;22(6):829. doi: 10.3892/ol.2021.13090. Epub 2021 Oct 13.
Uromodulin (UMOD) is a glycoprotein that is selectively expressed on the epithelial cells of the thick ascending limb of Henle's loop and the early distal renal tubule. The present study aimed to investigate whether UMOD was associated with complement activation in patients with renal diseases. In addition, its biological function was examined . The expression levels of UMOD and complement components, including C1q, C3, C4 and C3a, and membrane attack complex (MAC) in the plasma of patients with IgA nephropathy (IgAN; n=58) and lupus nephritis (LN; n=36) were detected using ELISA, which was used to determine the association between UMOD expression and complement components. In addition, a simulated hypoxia-reoxygenation (H/R) model was used to stimulate UMOD expression in mouse inner medullary collecting duct cells. Additionally, the association between UMOD expression and complement components C1q and C3d at the cellular level was identified using western blotting and immunofluorescence, respectively. It was revealed that the plasma UMOD concentration was significantly decreased in patients with IgAN and LN compared with in healthy controls, and the levels of C3a and MAC were significantly increased in the plasma of patients with IgAN and LN. Furthermore, the plasma levels of C1q, C3 and C4 in patients with LN, but not in patients with IgAN, were significantly decreased compared with in healthy controls. The plasma levels of UMOD were negatively correlated with the plasma C3a and MAC concentrations. However, the plasma levels of UMOD were significantly and positively correlated with the plasma C1q concentration, but not with that of C3 and C4. It was identified that UMOD expression started to increase after 1 h of simulated H/R, and continued to increase at 6 and 12 h. In addition, cells with lower UMOD expression had higher C3d expression . Collectively, the present results suggested that UMOD was associated with severe complement activation and may be involved in complement-mediated immune protection by inhibiting complement activation in renal disease.
尿调节蛋白(UMOD)是一种糖蛋白,在髓袢升支粗段和远端肾小管起始段的上皮细胞上选择性表达。本研究旨在探讨UMOD是否与肾脏疾病患者的补体激活相关。此外,还检测了其生物学功能。采用酶联免疫吸附测定(ELISA)法检测了58例IgA肾病(IgAN)患者和36例狼疮性肾炎(LN)患者血浆中UMOD及补体成分(包括C1q、C3、C4和C3a)和膜攻击复合物(MAC)的表达水平,以确定UMOD表达与补体成分之间的关联。此外,利用模拟缺氧复氧(H/R)模型刺激小鼠髓质集合管细胞中UMOD的表达。另外,分别采用蛋白质印迹法和免疫荧光法在细胞水平鉴定UMOD表达与补体成分C1q和C3d之间的关联。结果显示,与健康对照相比,IgAN和LN患者血浆中UMOD浓度显著降低,IgAN和LN患者血浆中C3a和MAC水平显著升高。此外,与健康对照相比,LN患者血浆中C1q、C3和C4水平显著降低,而IgAN患者血浆中C1q、C3和C4水平无显著变化。血浆中UMOD水平与血浆C3a和MAC浓度呈负相关。然而,血浆中UMOD水平与血浆C1q浓度呈显著正相关,与C3和C4浓度无显著相关性。研究发现,模拟H/R 1小时后UMOD表达开始增加,并在6小时和12小时持续增加。此外,UMOD表达较低的细胞C3d表达较高。总体而言,目前的结果表明,UMOD与严重的补体激活相关,可能通过抑制肾脏疾病中的补体激活参与补体介导的免疫保护。